

magle group.

Q1, 2024
interim report

Jan-Mar '24

- Net sales amounted to 38.2 MSEK (38.7).
- EBITDA equalled 7.0 MSEK (7.5).
- Operating profit (EBIT) is 4.1 MSEK (4.3)
- Profit after tax amounted to 2.9 MSEK (2.9)
- Earnings per share SEK 0,3 (0,3) per share

Full year '23

- Net sales amounted to 170.4 MSEK (145.7).
- EBITDA equalled 31.1 MSEK (25.8).
- Operating profit (EBIT) is 18.0 MSEK (12.8)
- Profit after tax amounted to 12.2 MSEK (9.1)
- Earnings per share SEK 1,1 (0,9) per share

Period events

- Public bid announced for Amniotics AB.
- Enters into loan facilities amounting of 12 MSEK with two of the main shareholders, to be approved by the gerneral meeting.

After period

- Appointment of SmartPAN distributor in Singapore.
- Updated timetable of public bid for Amniotics AB.

Consolidated key figures	Jan-Mar 2024	Jan-Mar 2023	Jan-Mar 2022	Jan-Mar 2021	Jan-Mar 2020
Income Statement					
Revenue	38 224	38 653	30 239	30 429	38 793
R&D expenses	-1 872	-1 507	-1 504	-2 728	-734
Operating expenses	-38 131	-37 184	-29 150	-30 612	-41 175
Operating profit	4 155	4 303	4 588	784	187
Net financial items	-647	-756	246	496	351
Net profit	2 944	2 884	4 079	1 004	410
Balance Sheet					
Inventory	33 129	31 869	24 747	18 093	16 773
Intangible assets	85 690	77 716	72 902	28 966	27 159
Tangible assets	118 756	111 157	102 799	103 175	102 102
Total assets	290 694	269 683	257 050	212 877	197 050
Shareholders' equity	161 424	149 529	144 697	137 271	113 516
Share capital	540	540	540	540	500
Cash Flow Statement					
Cash flow from operating activities	3 977	-2 845	-5 013	3 683	2 607
Cash flow from investing activities	-10 030	-6 757	-1 649	-2 852	-1 915
Cash flow from financing activities	4 848	6 009	10 898	17 061	-7 331
Investments in intangible assets	-2 351	-1 587	-477	-6	-18
Investments in tangible assets	-7 679	-9 257	-1 064	-1 363	-1 897

CEO statement.

During the first quarter of 2024, we have increased our investments in DSM development to meet the increasing demand for our proprietary products. We have also taken steps to acquire the research company Amniotics by a public bid to the company's shareholders. A potential acquisition of Amniotics will include its cGMP-licensed facilities for the development and clinical manufacturing of advanced therapy medicinal products (ATMPs) and allow us to expand our business offering to new customer groups in the growing Nordic biotech arena.

Increasing interest in DSM-based products

We are continuously experiencing a growing demand for our DSM-based products, and as a consequence, we are allocating more resources to internal product development. Though the shift in focus has resulted in a slight decrease in the revenue stream from our development services, our performance was well in line with our expectations as our proprietary DSM-based products have rapidly become an increasingly important part of our business.

Magle Group announces intention to acquire Amniotics

On March 22, we announced a recommended public offer to the shareholders of Amniotics to tender all their shares to Magle Group. The outcome will be communicated at the beginning of May shortly after the offer is closed. We are very excited by the opportunity to bring Amniotics into the Magle family, and with that, all ongoing projects and clinical activities, including the company's cGMP-licensed facilities for the development and clinical manufacturing of advanced therapy medicinal products (ATMPs).

If the acquisition is completed the new facilities will enable Magle Group to broaden its service offering to this rapidly expanding field of medical product development and pave the way for long-term growth in both the CDMO and development areas of our business.

A steady course forward

During the first quarter, we had a slight year-on-year decrease in royalty revenues, yet the quarter's overall revenue and EBIT contribution remain robust – total net sales came in at SEK 38.2 million, representing a small decrease of 1 percent, and EBITDA continued to stay stabile with 18 percent at SEK 7.0 million. This achievement highlights the strong commercial appeal and potential of our DSM material science platform, alongside our state-of-the-art contract development and manufacturing services. In summary, we are looking forward to an exciting and eventful continuation of the year with excellent conditions for growing Magle Group's business in terms of both existing and new areas with the potential to provide long-term benefits to patients and our shareholders.

Malmö, 18th April 2024

Who we are.

Magle Group combines trusted contract manufacturing services with innovative starch-based medical technologies. Since acquiring Chemoswed in 2016 and subsequently incorporating Adroit Science and PharmaCept into our operations, our growth has been substantial.

Our primary mission is to make a significant positive impact on healthcare. We aim to lead in healthcare innovation, committed to delivering meaningful benefits to our stakeholders and positively influencing people's lives. Our values of quality, safety, collaboration, and agility underpin our efforts to bring innovative solutions to the market. The extensive expertise of our team and our advanced facilities play a crucial role in the development and delivery of groundbreaking products.

We address a vital market need by offering top-quality manufacturing services and pioneering starch-based products.

Our unique position, bolstered by our vast expertise and extensive clinical network, enables us to offer unmatched solutions, efficiently bringing to market products with considerable potential.

Since our expansion in 2016, our contract manufacturing business has not only grown but we have also successfully developed, obtained CE marking for, and launched four medical devices across diverse markets including Europe, the Middle East, Asia, and Latin America. These achievements affirm the effectiveness and potential of our business model.

At Magle Group, our ambitions extend far beyond merely producing products. We are dedicated to improving lives through scientific innovation and a focused commitment to patient outcomes. We are fully prepared to face the future, ready to embrace both the challenges and opportunities it presents, with the goal of continuing to push the boundaries of healthcare innovation.

Business model.

Magle Group's approach is focused on sustainability and increasing our earnings to support our activities. At the heart of our plan is to diversify how we make money and keep a balanced approach to costs in our key areas. This ensures we have a good balance between our income and expenses.

Our business relies on five main ways of making money, three of which come from our contract development and manufacturing services. These services range from developing to making products for the pharmaceutical and medical device industries. The other two sources of income come from our Degradable Starch Microspheres (DSM) technology, through licensing deals and selling our DSM products directly.

This strategy not only gives us a solid financial base but also allows us to take full advantage of the growth opportunities our DSM technology offers. By combining our manufacturing services with our DSM innovations, we plan to grow, increase profits, and create significant value for our investors. Our commitment to this approach shows our focus on long-term achievement and our skill in dealing with the healthcare market's challenges.



CDMO offerings.

In the Contract Development and Manufacturing Organization (CDMO) arena, Magle Chemoswed distinguishes itself by tackling the complex challenges of pharmaceutical development and production. Our contribution is vital in lowering the substantial failure rates of drug candidates, with 99.2% not advancing past trials and approvals. We provide a full suite of services, from formulation, addressing inefficiency and regulatory obstacles, to process development and scaling up, improving effectiveness and ensuring compliance.

Advanced capabilities

Our broad capabilities encompass top-notch manufacturing facilities and a wide range of specialised services like solid-state chemistry and lyophilisation. With our unwavering dedication to quality, following Good Manufacturing Practices (GMP), we guarantee the safety, effectiveness, and compliance of pharmaceutical products.

Key partnerships

As a key partner in the CDMO market, Magle Chemoswed provides deep expertise across formulation development, analytical testing, process optimization, and manufacturing, alongside regulatory and quality assurance support.

Our approach is tailored to meet the evolving needs of our partners, ensuring projects are efficiently managed and aligned with strategic goals. Magle Chemoswed's mission in the CDMO market is to streamline the pharmaceutical development process, offering a reliable, end-to-end service that mitigates risks and ensures the successful launch of innovative, compliant pharmaceutical products.

In a sector where success hinges on precision and reliability, Magle Chemoswed is a trusted partner, guiding clients through the complexities of bringing new drugs to market.





DSM.



Degradable Starch Microsphere (DSM) technology has been steadily gaining recognition. Originating from starch, a material known for its bio-compatibility and environmental sustainability, DSM technology has found its place in a variety of medical treatments.

DSM a proven technology

Our journey with DSM technology commenced over two decades ago, motivated by the ambition to utilise natural materials to address medical challenges. This approach has led to DSM becoming a fundamental component in numerous successful treatments globally, demonstrated by our products such as Arista®, SmartPAN®, SmartGel®, and EmboCept®. These products validate the safety, efficacy, and compatibility of DSM with the human body, showcasing our contributions towards enhancing healthcare innovations worldwide.

DSM future

The adaptability of DSM technology underlines its extensive potential as a platform for various medical applications, ranging from surgical interventions to advanced wound care. As we look towards the future, our focus is on further developing and broadening the applications of DSM, continually seeking ways it can meet the evolving challenges of healthcare.

Our dedication to employing DSM technology for improved patient care and ongoing innovation guides our path forward, signalling a future where it remains instrumental in elevating healthcare standards globally.

Innovative products to patients.

At Magle Group, we are driven by the significant potential of Degradable Starch Microspheres (DSM) to enhance patient care. Our in-depth understanding of DSM technology and its applications in medicine fuels our commitment to utilising this knowledge to develop innovative healthcare solutions. Inspired by nature, we focus on DSM technologies to effectively meet the needs of both patients and clinicians.

Scientfic led innovation

The development of each DSM-based product is deeply collaborative, involving our scientific teams working closely with clinics and research institutions to develop solutions that significantly improve patient outcomes.

We've established a comprehensive R&D framework and streamlined processes to manage the development of our DSM products from the initial discovery to clinical application. This encompasses preclinical testing, manufacturing, clinical trial design and execution, and regulatory submissions, facilitating a smooth progression from concept to clinical practice across our global operations.

DSM versatility

Magle Group is dedicated to advancing DSM technology to produce distinctive and potentially leading medical products. Our goal is to significantly enhance patient lives by equipping clinicians with new tools for more effective and personalised treatment options. Our expertise in DSM development underscores our commitment to delivering healthcare innovations that truly make a difference.



Research & development capabilities.

Magle Chemoswed's research and development (R&D) team is central to our leadership in the Contract Development and Manufacturing Organisation (CDMO) market. Our laboratories are equipped with the latest technology, staffed by a team of dedicated scientists and engineers focused on pioneering advancements in pharmaceutical and medical device development.

Wide range of expertise

Our team excels in formulation and process development, tackling the complex challenges of drug development, including inefficacy, safety, and regulatory compliance. Our precision in formulation ensures products are optimised for efficacy, safety, and consistency, critical for regulatory approval and extending shelf life.

In process development, we apply a systematic approach to refine and upscale drug manufacturing processes, enhancing efficiency and ensuring compliance with regulatory standards. This area of expertise is essential for successfully transitioning from lab-scale development to commercial production, maintaining quality and compliance.

Specialised knowledge leadership

Our analytical development services are comprehensive, covering everything from product release method development to characterisation. Additionally, we possess specialised knowledge in areas like solid-state chemistry, crucial for thorough project development. Our expertise also extends to lyophilisation and inhalation drug delivery, tackling the unique challenges associated with these methods.

Furthermore, our CDMO operations are instrumental in supporting and allocating resources for Degradable Starch Microspheres (DSM) research and development, enabling significant investment in DSM R&D.

Dedication to excellence

At the heart of Magle Chemoswed, our R&D team's mission is to drive excellence in the CDMO market. Through a combination of scientific rigour, specialised expertise, and a commitment to quality, we aim to develop products that surpass industry standards, thereby supporting our partners and improving patient outcomes.

Manufacturing capabilities.

Magle Chemoswed's standing within the Contract Development and Manufacturing Organisation (CDMO) market is highlighted by our extensive manufacturing operations.

Wide ranging expertise

Our expertise stretches from synthesising high-quality active pharmaceutical ingredients (APIs) to the creation of complex drug products, including liquid formulations and injectables, ensuring we meet our partners' varied requirements precisely.

Simple solutions for complex problems

We provide complex filling and finishing process, where modern automated lines ensure accuracy in our packaging solutions, from filling to the final packaging and labelling of products. We specialise in manufacturing orphan drugs and Degradable Starch Microspheres (DSM), involving production of small-scale batches for clinical trials up to large-scale commercial production.

World class facilities

Our facilities are equipped to support projects from early clinical phases to commercialisation, incorporating traditional manufacturing sites, contemporary automated lines, and specialist cleanroom facilities. This infrastructure enables a versatile manufacturing approach, accommodating the production demands of both conventional pharmaceutical products and innovative DSM formulations.

By marrying cutting-edge technology with specialised expertise and a firm commitment to quality, Magle Chemoswed guarantees the successful development and commercialisation of a broad spectrum of pharmaceutical products.

Our strategy not only meets but also anticipates the dynamic requirements of the industry, solidifying our reputation as a reliable partner in pharmaceutical manufacturing.

Quarterly report.

CONTENT

Manufacturing.

Magle Chemoswed's Contract Manufacturing Organisation team has demonstrated progress and resilience throughout the first quarter of 2024. Operating from our advanced 6,000 sqm facility in Malmö, Sweden, our team has continuously delivered on our promise of comprehensive manufacturing support, adhering to the highest GMP and ISO standards.

Our facilities, inclusive of a logistics center, ensure seamless production and delivery, underpinning our capabilities in active pharmaceutical ingredient (API) manufacturing, and specialized production suites dedicated to orphan drug substances and small-batch manufacturing for pre-clinical and clinical stage products.

In the first quarter, Manufacturing witnessed strong demand, propelled by the launch of DSM products and steady market interest. Active pharmaceutical ingredient (API) manufacturing remained stable, meeting quarterly expectations. The first quarter revenues from manufacturing were 18.8 MSEK (15.0).

We also saw strong manufacturing demand, emphasizing our operational efficiency and market credibility. This period reflects our capacity to fulfill rising manufacturing needs and solidifies our reputation as a reliable industry partner.

Development.

During the first quarter of 2024, Magle Chemoswed's Contract Development segment experienced a strategic slowdown in third-party projects due to a concentrated effort on advancing our internal DSM development projects, which are in a critical phase.

This focus has resulted in a number of development projects being handed over to the manufacturing teams as we push these initiatives closer to commercialisation stages. This deliberate shift highlights our commitment to prioritizing the development of DSM products, acknowledging their importance and potential impact.

Our actions reflect a strategic decision to allocate resources towards areas with the most significant potential for growth and success, even as we continue to manage and support external client projects within our capacity.

Despite the allocation of resources to the DSM products, our team has successfully managed to engage in several new customer projects. Moreover, this period was marked by generating revenues of 3.7 MSEK (4.9) in the quarter. This achievement underscores our ability to balance the intensive development of DSM products with the ongoing acquisition and execution of new client projects, demonstrating our operational efficiency.

Laboratories.

The Contract Laboratories team offers tailored analytical services to life science companies, working on a payment model. Based in Malmö and Lund, Sweden, our team focuses on characterising materials. This service is key to understanding the physical qualities of pharmaceutical solids, vital for achieving their best form. This understanding affects the material's behavior, how well it can be made into a formula, its manufacturability, stability, and how it looks. Our team is skilled in carrying out a variety of characterization studies, from standard to more complex ones.

In 2024, we saw a stable demand for our material characterisation services. This continuous demand highlights the critical nature of our services in ensuring the high quality and efficacy of pharmaceutical materials. Our ability to keep up with these demands not only demonstrates our expertise but also reflects the confidence our clients have in our abilities, underlining the indispensable role of material characterisation in the pharmaceutical development process. In teh first quarter of 2024 revenues were 3.4 MSEK (3.6).

This consistent demand has led us to consider expanding our facilities and investing in new technologies to enhance our service offerings. By doing so, we aim to not only meet but exceed client expectations, reinforcing our position as a leader in the field of material characterisation.

DSM.

The DSM team of the Magle Group generates income through direct product sales by our sales team and through our ongoing royalty arrangement with Becton Dickinson related to the sale of their Arista™ product. EmboCept® S DSM 50 is authorised for use as an embolic agent for the chemo-embolization of inoperable liver and lung tumours. It's well-established and was recognised as a standard treatment in 2022. SmartPAN® is a leading medical device for detecting pancreatic fluid leaks during either open or minimally invasive surgical procedures. If pancreatic fluid is not detected, it can cause significant postoperative complications for patients.

AXXO® Woundgel is an allergy-free hydrogel developed from our exclusive microsphere technology. It's a unique wound hydrogel that includes an antimicrobial in DSM, formulated as a gel to help initiate healing.

Regarding DSM royalties, the Magle Group has a long-term license agreement with Becton Dickinson that is now specifically related to the sales of their Arista™ product. This agreement is expected to provide long-term revenues. In teh first quarter of 2024 the combiend revenues releated to DSM was 16.2 MSEK (18.6).

Pipeline.

Magle Group's DSM pipeline is at the forefront of medical innovation, focusing on developing advanced solutions to address a range of healthcare challenges. Our pipeline showcases our commitment to leveraging Degradable Starch Microsphere (DSM) technology to create products that offer significant improvements over existing treatments in terms of efficacy, safety, and patient experience.

EmboCept® M

EmboCept® M represents a pioneering approach to treating benign prostatic hyperplasia (BPH) through prostatic artery embolization. This product candidate stands out for its potential to offer key advantages over currently available treatments. Its design focuses on easy administration and controlled degradation, ensuring biocompatibility and the possibility of enhanced treatment efficacy for patients. EmboCept® M is poised to redefine the standard of care for BPH, providing a less invasive and more effective treatment option.

EmboCept® L

Developed as an embolic agent, EmboCept® L targets the treatment of benign uterine fibroids. This innovative product candidate brings forth potential treatment advantages, including the possibility of repeat administrations and biocompatible degradation. EmboCept® L is designed to offer a non-surgical alternative for managing uterine fibroids, promising a significant step forward in patient care and treatment flexibility.

SmartBone

The SmartBone project is focused on revolutionizing dental bone tissue engineering. It aims to develop a new composition that not only induces but also facilitates the repair and regeneration of tissue. Incorporating an mRNA molecule, SmartBone is designed to accelerate normal physiological repair processes. This groundbreaking approach has the potential to significantly advance dental and bone tissue engineering, offering new solutions for tissue repair and regeneration.

Magle Group's DSM pipeline reflects our dedication to pushing the boundaries of medical science, developing products that not only meet but exceed current treatment standards. Through our innovative use of DSM technology, we are committed to improving patient outcomes and advancing healthcare solutions worldwide.

Financial reports.

Income statement.

TSEK	2024 Jan-Mar	2023 Jan-Mar	2023 Jan-Dec	2022 Jan-Dec
Revenues				
Net sales	**38 224**	38 653	170 440	145 677
Work performed by the company for its own use and capitalized	**384**	279	1 056	2 305
Other revenues	**3 678**	2 555	11 692	8 394
Total	**42 286**	**41 487**	**183 188**	**156 376**
Change in inventory of finish goods	**4 747**	3 102	19 141	25 990
Raw materials and consumables	**-8 476**	-7 224	-36 716	-39 857
Other external expenses	**-14 131**	-11 793	-52 229	-48 548
Personnel costs	**-17 350**	-18 097	-78 625	-64 881
Depreciation and amortization	**-2 884**	-3 172	-13 104	-12 979
Other operating expenses	**-37**	-	-3 646	-3 589
Total operating expenses	**-38 131**	**-37 184**	**-165 179**	**-143 594**
Operating profit/loss	**4 155**	**4 303**	**18 009**	**12 782**
Profit/loss from financial items				
Financial income	**2**	4	291	11
Financial expenses	**-649**	-760	-3 215	-1 769
Profit before tax	**3 508**	**3 547**	**15 085**	**11 024**
Taxes for the period	**-564**	-663	-2 917	-1 879
Net profit/loss for the period	**2 944**	**2 884**	**12 169**	**9 145**

Condensed statement of comprehensive income.

TSEK	2024 Jan-Mar	2023 Jan-Mar	2023 Jan-Dec	2022 Jan-Dec
Profit/loss for the period	2 944	2 884	12 169	9 145
Other comprahensive income/loss	**256**	-112	-68	-375
Total comprehensive income for the period	**3 200**	**2 772**	**12 101**	**8 770**

Earnings per share.

	2024 Jan-Mar	2023 Jan-Mar	2023 Jan-Dec	2022 Jan-Dec
Equity holders of the parent				
Earnings per share before dilution, share issue	0,27	0,27	1,13	0,85
Earnings per share after dilution, share issue	0,27	0,27	1,13	0,85
Profit/loss for the period	2 944	2 884	12 169	9 145
Average number of shares before dilution, share issue	10 800	10 800	10 800	10 800
Average number of shares after dilution, share issue	10 800	10 800	10 800	10 800

Condensed consolidated balance sheet.

TSEK	March 2024	March 2023
ASSETS		
Intangible assets	85 690	77 716
Tangible assets	118 756	111 157
Deferred tax asset	2 706	1 792
Other non-current assets	661	567
Total non-current assets	**207 813**	**191 232**
Inventories	33 129	31 869
Trade receivables	22 357	18 612
Other operating receivables	21 382	21 686
Cash and cash equivalents	6 013	6 284
Total current assets	**82 881**	**78 451**
TOTAL ASSETS	**290 694**	**269 683**
EQUITY AND LIABILITIES		
Equity attributable to equity holders of the parent	**161 424**	**149 529**
Liabilities to credit institutions	32 582	31 583
Liabilities to associated companies	-	3 000
Leasing debt	9 295	4 613
Deferred tax liability	8 511	8 569
Other longterm liabilities	606	7 852
Total non-current liabilities	**50 994**	**55 617**
Liabilities to credit institutions	26 070	21 147
Leasing debt	3 944	2 280
Trade payables	13 881	13 759
Liabilities to associated companies	3 000	-
Other operating liabilities	31 381	27 351
Total current liabilities	**78 276**	**64 537**
TOTAL EQUITY AND LIABILITIES	**290 694**	**269 683**

Condensed statement of changes in equity.

TSEK	Share capital	Other paid in capital	Translation reserves	Retained earnings incl. P/L for year	Total equity
As at 1 January 2023	**540**	**118 037**	**-1 050**	**29 240**	**146 767**
Profit/loss as at 31 December 2023				12 169	12 169
Other comprehensive income as 31 December 2023:Translation difference			-68		-68
Warrant program				-643	-643
Equity as at 31 December 2023	**540**	**118 037**	**-1 118**	**40 766**	**158 225**
As at 1 January 2024	**540**	**118 037**	**-1 118**	**40 766**	**158 225**
Profit/loss as at 31 March 2024				2 944	2 944
Other comprehensive income as at 31 March 2024:Translation difference			-16	272	256
Equity as at 31 March 2024	**540**	**118 037**	**-1 134**	**43 981**	**161 424**

Condensed consolidated statement of cashflows.

	2024 Jan-Mar	2023 Jan-Mar	2023 Jan-Dec	2022 Jan-Dec
Profit/loss before tax	3 508	3 547	15 085	11 024
Adjustments for depreciation, amortization and other non-cash items:	1 198	2 719	12 479	14 605
Income tax paid	-1 595	-453	-2 372	-3 547
Changes in working capital	-3 422	-9 111	-9 863	7 529
Net cash flow from operating activites	**-311**	**-2 845**	**15 331**	**12 466**
Acqusition of subsidiary companies	-	-	-	-
Payment of Acquisition of subsidiary company	-	-986	-5 284	-4 620
Investments in assets	-5 742	-5 771	-15 122	-16 871
Net cash flows from investing activites	**-5 742**	**-6 757**	**-20 406**	**-21 491**
Debt incurred	-	-	34 601	8 049
Amortization of bank loan	-288	-481	-34 540	-1 981
Loan associated companies	-	-	-	3 000
Amortization of leasing	-492	-1 252	-3 695	-3 300
Change in bank overdraft	5 628	7 741	6 802	9 037
Repayment of warrant program	-	-	-643	-
Net cash flow from financing activities	**4 848**	**6 009**	**2 524**	**14 805**
Net cash flow	**-1 205**	**-3 594**	**-2 551**	**5 781**
Cash and cash equivalents at beginning of period	7 079	9 878	9 878	3 985
Currency effects	139	-	-248	113
Cash and cash equivalents at end of period	**6 013**	**6 284**	**7 079**	**9 878**

Condensed income statement of parent company.

TSEK	2024 Jan-Mar	2023 Jan-Mar	2023 Jan-Dec	2022 Jan-Dec
Net sales				
Intercompany revenue	5 395	3 378	14 780	9 908
Other revenues	34	72	134	26
Total	**5 429**	**3 450**	**14 914**	**9 934**
Other external expenses	- 2 220	-860	-3 045	-2 357
Personnel costs	-3 492	-2 621	-12 661	-9 696
Other operating expenses	116	-	-1 378	-
Total Costs	**- 5 596**	**-3 481**	**-17 084**	**-12 053**
Operating profit/loss	**-167**	**-31**	**-2 170**	**-2 119**
Net financial items	1	126	-89	-213
Profit loss after financial items	**-166**	**95**	**-2 259**	**-2 332**
Appropriations	-	-	2 305	2 377
Taxes for the period	34	-20	-42	-21
Net profit/loss for the period	**-132**	**75**	**4**	**24**

Condensed balance sheet of parent company.

TSEK	March 2024	March 2023
ASSETS		
Current assets	335	335
Non-current assets	88 864	88 462
Other receivables	45 234	27 616
Prepaid expenses	1 174	2 484
Cash and cash equivalents	65	287
TOTAL ASSETS	**135 672**	**119 184**
EQUITY AND LIABILITIES		
Equity		
Restricted equity	540	540
Unrestricted equity	90 542	91 393
Total equity	**91 082**	**91 933**
Non-current liabilities	-	7 231
Current liabilities	44 590	20 020
TOTAL EQUITY AND LIABILITIES	**135 672**	**119 184**

Financial notes.

Financial notes.

Note 1: General information, accounting principles

This interim report was prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. The parent company's reporting has been prepared in accordance with RFR 2, Reporting for Legal Entities, and the Swedish Annual Accounts Act. Accounting principles have been applied as reported for the Annual Report per 31 December 2019. New or amended standards or interpretations of standards effective as of 31 December 2023 have not had any significant impact on Magle Chemoswed's financial statements.

Note 2: Significant risks and uncertanties

The Group is exposed to various financial risks. The business is impacted by many factors that could affect the Group's result and financial position. It is Magle Chemoswed's strategy to continuously identify and manage risks. Financial risk management is described in the Annual report 2023.

Note 3: Transactions with related parties

The financial reports include costs related to transactions between Magle Chemoswed and related parties.

Related party	Service	2024 Jan-Mar	2023 Jan-Mar	2023 Jan-Dec	2022 Jan-Dec
TSEK					
Hans Henrik Lidgard (Chairman of the Board)	Office rent	**80**	-	**150**	-
Magle AB	Acqusition of dormant subsidiaries	-	-	**119**	-

Note 4: Financial assets and liabilities

Fair values of current financial assets and liabilities are assessed agree with values accounted for.

Note 5: Revenues

Operating units are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker is the function responsible for allocating resources and assessing the performance of the operating unit. In the Magle Chemoswed Group, the CEO has been identified as the chief operating decision maker who evaluates the Group's financial position and performance and makes strategic decisions. The CEO analyzes and monitors the business performance based on the Group as a whole.

By nature of income	2024 Jan-Mar	2023 Jan-Mar	2023 Jan-Dec	2022 Jan-Dec
TSEK				
Contract manufacturing	18 796	15 016	54 653	49 884
Contract development	3 680	4 868	15 320	23 092
Contract laboratories	3 412	3 575	14 961	14 714
DSM license and sales	16 179	18 575	87 069	57 987
Business unit sales	2 495	4 432	-	-
Eliminations	-6 337	-7 812	-20 297	-2 847
Total	**38 225**	**38 653**	**170 440**	**145 677**

Financial notes.

By company	2024 Jan-Mar	2023 Jan-Mar	2023 Jan-Dec	2022 Jan-Dec
TSEK				
Magle Chemoswed AB	36 740	35 063	159 446	131 621
Magle Chemoswed Holding AB	5 395	3 378	14 780	9 908
Adroit Science AB	235	392	1 670	3 367
Magle PharmaCept GmbH	2 192	4 552	14 841	16 888
Eliminations	- 6 337	-4 732	-20 297	-16 107
Total	**38 224**	**38 653**	**170 440**	**145 677**

By country	2024 Jan-Mar	2023 Jan-Mar	2023 Jan-Dec	2022 Jan-Dec
TSEK				
Sweden	10 818	4 830	48 336	28 753
Europe excluding Sweden	14 754	12 792	49 235	62 777
Other territories	18 990	16 599	93 136	70 254
Eliminations	-6 337	-4 732	-20 297	-16 107
Total	**38 224**	**38 653**	**170 440**	**145 677**

Note 6: number of shares

Ordinary Shares	Number of shares	Potential shares
31 December 2019	500	-
30 June 2020	10 000 000	225 000
4 January 2021	10 800 000	225 000
30 September 2023	10 800 000	-

Note 7: Warrants

At period end, the management elected to not to exercise the warrant program. The warrant program was executed in June 2020 and should have exercised in October 2023.The effect on equity amounts to 543 TSEK in 2023.

Warrant program	Number of options	Equals number of shares
Balance June 30, 2020	**225 000**	**225 000**
Balance December 31, 2020	**225 000**	**225 000**
Balance March 31, 2024	**-**	**-**

Board of directors.

Hans Henrik Lidgard
Founder and Chairman

Born 1946. Chairman since 2016, board member since 2013.

Mats Pettersson
Board Member

Born 1945. Board member since 2016.

Sven-Christer Nilsson
Board Member

Born 1944. Board member since 2016.

Martin Lidgard
Board Member

Born 1977. Board member since 2021.

Malin Malmsjö
Board Member

Born 1973. Board member since 2016.

Joel Eklund
Board Member

Born 1980. Board member since 2020.

Claudia Lindwall
Staff Representative

Born 1963. Employee representative since 2021.

Ingela Fritzon
Staff Representative

Born 1964. Employee representative since 2019.

Statement.

The Board of Directors certify that the interim report, to the best of their knowledge, provides a fair overview of the parent company's and the group's operations, financial position and results and describes the material risks and uncertainties faced by the parent company and the companies included in the group.

FORTHCOMING DISCLOSURES OF INFORMATION

FINANCIAL CALENDAR	DATE
ANNUAL GENERAL MEETING 2024	25TH OF APRIL, 2024
INTERIM REPORT Q2 2024	18TH OF JULY, 2024
INTERIM REPORT Q3 2024	24TH OF OCTOBER, 2024
FULL YEAR AND INTERIM REPORT Q4 2024	26TH OF FEBRUARY, 2025
ANNUAL REPORT 2024	26TH OF MARCH, 2025

CONTACT INFORMATION

Justin Pierce, CEO, phone +46 (0)70 593 58 21, Justin.Pierce@maglechemoswed.com

Vator Securities is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0) 8 5800 65 99.